From the Journals

Midodrine reduces fainting in young patients


 

FROM ANNALS OF INTERNAL MEDICINE

Study limitations

Limitations of the new study include its small size and short observation period, the authors wrote. Additionally, a large proportion of patients enrolled were also from a single center in Calgary that specializes in syncope care. Twenty-seven patients in the trial stopped taking their assigned medication during the year observation period, but the authors concluded these participants “likely would bias the results against midodrine.”

For doctors considering midodrine for their patients, it’s critical to confirm the diagnosis and to try patient education first, Dr. Sheldon advised.

Lifestyle factors like hydration, adequate sodium intake, and squatting or lying down when the syncope is coming on can sufficiently suppress syncopes in two-thirds of patients, he noted.

This is a treatment for young people, Dr. Sandhu said. The median age in the trial was 35, so patients taking midodrine should be younger than 50. Midodrine is also not effective in patients with high blood pressure or heart failure, she said.

“[Midodrine] is easy to use but kind of a pain at first,” Dr. Sheldon noted. Every patient should start out taking 5 mg doses, three times a day – during waking hours. But then you have to adjust the dosage, “and it’s tricky,” he said.

If a patient experiences goosebumps or the sensation of worms crawling in the hair, the dose might be too much, Dr. Sheldon noted.

If the patient is still fainting, first consider when they are fainting, he said. If it’s around the time they should take another dose, it might be trough effect.

Dr. Sandhu was not involved in the study, but Cedar Sinai was a participating center, and she considers Dr. Sheldon to be a mentor. Dr. Sandhu also noted that she has published papers with Dr. Sheldon, who reported no conflicts.

Pages

Recommended Reading

SUSTAIN FORTE: Higher-dose semaglutide safely boosts glycemic control, weight loss
Clinician Reviews
Heart failure med undertreatment because of older age common, flouts evidence
Clinician Reviews
New drug, finerenone, approved for slowing kidney disease in diabetes
Clinician Reviews
South Asian ancestry associated with twice the risk of heart disease
Clinician Reviews
Drinking coffee not linked to increased arrhythmia risk in new study
Clinician Reviews
Cycling linked to longer life in people with type 2 diabetes
Clinician Reviews
Analysis supports CAC for personalizing statin use
Clinician Reviews
Diabetes duration linked to increasing heart failure risk
Clinician Reviews
More on GRADE: Cognitive deficits linked to CV risk factors in T2D
Clinician Reviews
ARBs equal ACE inhibitors for hypertension, and better tolerated
Clinician Reviews